Mumbai: Rubicon Research Limited has filed its Draft Red Herring Prospectus (“DRHP”) with market regulator Securities and Exchange Board of India (“SEBI”). Rubicon Research is a pharmaceutical formulation company driven by innovation through focused research and development, with a growing portfolio of specialty products and drug-device combination products targeting regulated markets and in particular the United States. On a peer group basis (out of six listed Indian companies assessed by F&S and Company), Rubicon Research is the only Indian pharmaceutical company focused solely on regulated markets. (Source: F&S Reports).
The Company’s Initial Public Offering comprises a fresh issue of up to ₹ 5,000 million and an offer for sale of up to ₹ 5,850 million by the promoter selling shareholder, General Atlantic Singapore RR Pte Ltd. The net proceeds from the fresh issue offer may be used by the Company to prepay or repay all or certain of its outstanding borrowings, finance inorganic growth through undisclosed acquisitions and other strategic initiatives and general corporate purposes. The proceeds from the Offer for Sale will be received by the selling shareholder, General Atlantic Singapore RR Pte Ltd.
(Anil Bedaag)
 with market regulator Securities and){kind=link}